California Institute for Regenerative Medicine
Overview
California Institute for Regenerative Medicine is a state agency that funds research and clinical trials in stem cell, gene therapy, and regenerative medicine to accelerate the development of transformative treatments.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Humacyte | Sep 2017 | Grant | Lead |
| Senti Biosciences | Jun 2024 | Grant | Co-investor |
| Scribe Therapeutics | Jun 2026 | Grant | Co-investor |
| Juvena Therapeutics | Feb 2022 | Grant | Co-investor |
| Rejuvenate Bio | Jul 2024 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is California Institute for Regenerative Medicine based?
California Institute for Regenerative Medicine is headquartered in South San Francisco, California, United States.
When was California Institute for Regenerative Medicine founded?
California Institute for Regenerative Medicine was founded in 2004.
How many portfolio companies does California Institute for Regenerative Medicine have?
California Institute for Regenerative Medicine has 59 portfolio companies in Caplight's dataset.
What are some companies in California Institute for Regenerative Medicine's portfolio?
Portfolio companies visible on Caplight include Humacyte, Senti Biosciences, Scribe Therapeutics, Juvena Therapeutics, Rejuvenate Bio.
What was California Institute for Regenerative Medicine's most recent investment shown here?
California Institute for Regenerative Medicine's most recent investment in this portfolio sample was in Scribe Therapeutics in 2026.
What sectors does California Institute for Regenerative Medicine focus on?
California Institute for Regenerative Medicine focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Consumer & Commerce.
What company stages does California Institute for Regenerative Medicine focus on?
California Institute for Regenerative Medicine typically invests at the MultiStage stage.
What is California Institute for Regenerative Medicine's AUM?
California Institute for Regenerative Medicine's assets under management are estimated between $8.5B and $8.5B.